Tag: Real-World Evidence (RWE)
EU HTA Joint Clinical Assessments: 7 Critical Pharma Mistakes
EU HTA Joint Clinical Assessments (JCA): The 7 Critical Mistakes Pharma Companies Must Avoid Before Their First Submission The European healthcare landscape is undergoing one of the most significant transformations in decades. With the implementation of the European Union Health Technology Assessment (EU HTA) Regulation and the introduction of Joint Clinical Assessments (JCA), pharmaceutical and…
Regulatory-Grade AI and Living Evidence
Why Regulatory-Grade AI & Living Evidence Are Replacing Traditional RWE Models in Pharma A Turning Point for Real-World Evidence in Pharma Real-World Evidence (RWE) has become a cornerstone of pharmaceutical decision-making. Regulators, HTA bodies, and payers increasingly rely on RWE to support approvals, reimbursement decisions, and post-market monitoring. However, as expectations rise, traditional RWE models…
